Remi Gaston-Dreyfus - 13 Jun 2023 Form 4 Insider Report for Bionik Laboratories Corp.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 13 Jun 2023
Net transaction value: +$1,861,727
SEC form: 4
Accepted by SEC: 21 Jun 2023, 10:59:27 UTC
Prior SEC filing: 21 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Remi Gaston-Dreyfus

Key filing fact

Remi Gaston-Dreyfus filed Form 4 for Bionik Laboratories Corp. on 21 Jun 2023.

Key facts

This page summarizes Remi Gaston-Dreyfus's Form 4 filing for Bionik Laboratories Corp..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Jun 2023, 10:59.

Change

Previous filing in this sequence was filed on 21 Jun 2023.
Current net transaction value: +$1,861,727.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BNKL transaction

Common Stock, par value $0.001 per share

Conversion of derivative security

Transaction value: $1,861,727
Shares: +3,102,878
Change %: +171%
Price: $0.6000
Shares after: 4,917,749
Date: 13 Jun 2023
Ownership: Shares held through GD Holdings and Lombard International Assurance SA
Footnotes: F1, F2

BNKL holding

Common Stock, par value $0.001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 61,256
Date: 13 Jun 2023
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Effective as of June 13, 2023, an aggregate amount of approximately $5,171,463 of principal and accrued interest in outstanding convertible debt held by GD Holdings converted in accordance with its terms into 3,102,878 shares of the Issuer's common stock.

Footnote F2

Includes 17,476 exchangeable shares of the Issuer's subsidiary.